Summary.-The metal complexes Pd(MP)2 2H20, Pt(MP)22H20 (MPH=6-mercaptopurine), Pt(AMP)2-3H20 and Pd3(AMP)4C12(AMPH)-4H2O (AMPH=thioguanine) have been isolated. They were screened for anti-tumour activity in the L-1210 lymphoid leukaemia test system in mice. All 4 show marked anti-tumour activity, the complex Pt(AMP)2 *3H20 giving a T/C of 185 at the optimum dosage. However, the anti-tumour activity of the metal complexes is somewhat less than that shown by the parent purines under the same conditions.
THE effectiveness of 6-mercaptopurine (I; MPH) and related compounds in the treatment of leukaemias was reported in 1954 (Miner) and the 2-amino derivative, thioguanine (II; AMPH) has been widely used in the treatment of various types of cancer. Consequently, as part of our study of metal chelates* as potential anticancer agents, we have prepared palladium (Pd) and platinum (Pt) complexes of these purines and had them screened in the LI 210 lymphoid leukaemia test system.
The formation constants of the nickel (II), cobalt(II), lead(II), and zinc(II) complexes of 6-mercaptopurine were determined by Cheney et al. (1959) and the isolation of the metal complexes Met(MP)2 n-H20 (Met= Co, Ni, Cd; n 1, 2, 5, resp.) was reported by Ghosh and Chatterjee (1964) . Several anionic complexes of cobalt(III) have also been reported (Brigando and Colaitis, 1967) . Kirschner et al. (1966) nitrogen at position number 7 in the imidazole ring to yield the ci8 square-planar monomeric complex (III). The cis configuration is favoured relative to the trans configuration for transition metal complexes of thiolo ligands (Das et al., 1974) . On the other hand, since imidazole nitrogen is a poor donor, it is possible that the deprotonated purine behaves as a unidentate ligand, being bound to the metal atom via the sulphur atom only, yielding the polymeric thiolo-bridged complex (IV; R==purine moiety). Any other structure, involving nitrogen bonding, is unlikely in view of the high affinity of Pd (II) and Pt(II) for sulphur bonding. certainty, but the polymeric structure (V) is a possibility. The metal complexes were screened for anti-tumour activity in the lymphoid leukaemia L1210 test system and the results were compared with those for the purines under similar conditions. Preparation of Metal Chelates Bis(6-purinethiolo)palladium(JI) Dihydrate.
-A solution of 0 7 g potassium tetrachloropalladate(II) 30 ml in water was added to a suspension of 0 7 g finely powdered 6-mercaptopurine monohydrate (Aldrich Chemical Co., Milwaukee) in 50 ml ethanol. N, 25-2; Pd, 24-1%).
Bis(6-purinethiolo)platinum(ll1) Dihydrate. -A solution of 0-95 g potassium tetrachloroplatinate(II) in 30 ml water was added to a suspension of 0 75 g finely powdered 6-mercaptopurine (Aldrich) in 50 ml ethanol. The mixture was heated on the steam bath for 30 min and the resultant reddish-brown platinum complex was filtered off, washed with hot ethanol, and dried in vacuo over silica gel. Yield, 1-0 g (Found: C, 23-7; H, 1-7; N, 20-9; Pt, 36-5%. Calcd. for CjOHjON8O2PtS2: C, 22-5; H, 1-9; N, 21-0; Pt, 36-5%).
Dichlorotetrakis(2 -aminopurinethiolo) -2 -amino-6-mercaptopurinetripalladium(II) Tetrahydrate.-Asolutionof 1 2g potassiumtetrachloropalladate in 50 ml water was added to a suspension of 1-0 g finely powdered 2-amino-6-mercaptopurine (Aldrich) in 50 ml ethanol. The mixture was heated on the steam bath for 90 min with stirring. The deposite of light brown palladium complex was filtered off, washed with hot ethanol, and dried in vacuo over silica gel. Yield, 1-5 g. (Found, on different preparations: C, 23-2, 22-7; H, 1-9, 2-0; Cl, N, Pd, 24 .0%. Calcd. for C25H30Cl2N2504Pd3C12: C, 23-2; H, 2-3; Cl, 5-6; N, 27-0; Pd, 24.6%).
Bis(2 -amino -6 -purinethiolo)platinum (II) Trihydrate.-A solution of 1-0 g potassium tetrachloroplatinate(II) in 30 ml water was added to a suspension of 0-75 g finely powdered 2-amino-6-mercaptopurine (Aldrich) in 
Screening of Compounds
The screening was carried out in laboratories associated with the U.S. National Cancer Institute, viz. A. D. Little Inc., U.S.A., Southern Research Institute, U.S.A., and Institut Jules Bordet, Brussels, Belgium.
The screening was in accordance with the screening protocol for lymphoid leukaemia L1210 (Cancer Chemotherapy National Service Centre, 1959) . The animals used were mice, weighing 18-22 g, of a single sex for any one experimental group. The number of animals in each test group and control group was usually 6 (sometimes 3 or 10). The mice were inoculated i.p. with 0-1 ml of diluted ascitic fluid containing 105 cells of the 2  2  2  2  2  3  3  3  3  3  3  3  3  3  3  2  2  4  2  4  2  4  4  2  2  2  3  3  3  3  3  3  3  3  3  3  3 lymphoid leukaemia L1210. On the next day, the mice were injected i.p. with a suspension of the compound being tested; for the purines the vehicle was alkali diluted with saline and for the metal complexes the vehicle was saline with Tween-80. A total of 2-4, usually 3, injections were given at 4-day intervals. Toxicity was evaluated as survival 5 days after the injection, which was practically 100%.
The results of the screening were evaluated after 30 days on the basis of survival. For the 105-cell inoculum in the L1210 leukaemia screen, the mean day of death for untreated control mice is usually between 8 and 11 days. The experiment was evaluated on Day 30 even if some animals were still alive on that day. The T/C percentage was calculated from the mean survival time of the test and control mice. For example, if the mean survival time of the untreated control mice was 9-1 days and for the treated mice it was 12-8 days, then T/C was 140%.
RESULTS
A summary of the screening data is given in Table I , and some typical results are given in Table II . A T/C (Test evaluation/Control evaluation x 100) of 100 means that the compound has no effect in either decreasing or increasing the tumour. A T/C . 125 was taken to indicate significant anti-tumour activity.
DISCUSSION
From the data listed in Table I it can be seen that all 4 metal complexes display considerable anti-tumour activity. The Pd complex of 6-mercaptopurine is almost as effective as an anti-tumour agent as 6-mercaptopurine itself, whereas the activity of the Pt complex is considerably less. On the other hand, the Pt complex of thioguanine has a greater anti-tumour activity than the Pd complex, though this is considerably less than that of the purine.
It should be pointed out that higher values of T/C have been obtained for these purines in the L1210 test system under different testing conditions. For example, a T/C of 337 has been obtained for thioguanine at a dose level of 0 50 mg/kg per injection with 32 daily injections and evaluation on the 60th day. However, if meaningful comparisons are to be made for the relative anti-tumour activities of the purines and their metal chelates, the screening must be done under the same conditions.
Since there is still some doubt about the selective action of purines such as 6-mercaptopurine on tumour cells, it would be pointless to speculate on the mode of action of their Pd and Pt complexes.
The metal complexes are virtually insoluble in all common solvents and are non-toxic at doses up to 400 mg/kg. Their anti-tumour activity, although appreciable, appears to be significantly less than that of their parent purines.
